A study published in the New England Journal of Medicine found that for patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer who had not received prior treatment, nivolumab plus ipilimumab resulted in longer progression-free survival compared to chemotherapy. In the trial, patients were randomly assigned to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy with or without targeted therapies. The results showed that nivolumab plus ipilimumab was superior to chemotherapy in terms of progression-free survival outcomes. This study was funded by Bristol Myers Squibb and Ono Pharmaceutical, who manufacture nivolumab and ipilimumab.
Source link
Study finds increased survival with nivolumab plus ipilimumab vs. chemo for metastatic colorectal cancer
